Instrument for treating benign prostatic hyperplasia
By designing catheters and microneedle devices with multiple degrees of freedom adjustment, the problems of position adjustment in the prior art are solved in the urethra and blind spots of treatment, and efficient and damage-free treatment of prostate hyperplasia is achieved.
Patent Information
- Application Number
- CN202421408104.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-19
- Publication Date
- 2025-07-29
- Estimated Expiration
- 2034-06-19
AI Technical Summary
The existing prostate hyperplasia treatment devices are prone to friction and pulling with the cavity when the position is adjusted, and it is difficult to effectively treat tissues close to the urethra, resulting in recurrence.
An instrument including a catheter, a microneedle and a handle brake is designed. Through the micro-holes on the catheter and the slidable microneedle, combined with the cooperation of the support part, the positioning part and the pushing part, a multi-degree of freedom position adjustment is achieved. The puncture part of the microneedle is equipped with different depths and conductive areas to form a body energy field to cover the treatment blind spot.
It realizes efficient and multi-degree freedom of prostate tissue treatment, reduces frictional damage between the instrument and the urethra, improves the treatment effect and efficiency, and prevents recurrence.
Smart Images
Figure CN223158424U_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the technical field of medical devices, and particularly to a device for treating benign prostatic hyperplasia. Background Art
[0002] Existing methods for treating diseases of prostate hypertrophy include surgical operations, less invasive ablation device interventions, etc. For example, electro-surgery or mechanical tissue extraction of intra-capsular prostate tissue is used, and thermal ablation or cryoablation is performed on the intra-capsular prostate tissue. During the treatment process of the ablation device intervention, a slender tube needs to be inserted into the human urethra.
[0003] With the development of technology, radiofrequency ablation methods have emerged. The radiofrequency current passes through the tissue, generating a continuously changing electric field. The electric field exerts a force on the electrolyte ions in the tissue, causing them to move back and forth at a very high speed. The friction and impact of the ion flow in the tissue generate a magnetic field / heat, which is manifested as a field effect / thermal effect in the tissue. When the radiofrequency current flows through human tissue, due to the rapid change of the electromagnetic field, the positive and negative ions in the cells move rapidly. Thus, the friction between them and other molecules and ions in the cells causes the temperature of the lesion site to rise, resulting in the evaporation, drying, shrinkage and shedding of water inside and outside the cells, and even aseptic necrosis, so as to achieve the treatment purpose.
[0004] Existing puncture ablation instruments generally use umbrella-shaped needles or single-needle ablation methods during the treatment process, making it difficult to adjust the position and prone to friction and pulling with the cavity, thus causing damage. At the same time, when treating benign prostatic hyperplasia, it is often impossible to achieve good treatment of the prostate tissue close to the urethra, resulting in the recurrence of benign prostatic hyperplasia. Summary of the Utility Model
[0005] Based on this, in view of the above problems, it is necessary to provide a device for treating benign prostatic hyperplasia. When using this device to treat prostate tissue, multi-degree-of-freedom position adjustment can be simply achieved, and the urethra will not be damaged. At the same time, it can also achieve good treatment effects on the prostate tissue close to the urethra.
[0006] The technical solution provided by the present disclosure is as follows:
[0007] A device for treating benign prostatic hyperplasia, comprising:
[0008] Catheter, microneedle and handle brake; the catheter is provided with a plurality of micropores arranged at intervals in a first direction and a second direction; the microneedle is slidably arranged inside the catheter, and the distal end can extend out of the catheter through the micropores; the handle brake includes a support portion, a positioning portion, a limiting portion and a pushing portion connected in sequence. One end of the support portion is connected to the proximal end of the catheter, and the other end is movably connected to the positioning portion; the positioning portion cooperates with the support portion to enable the microneedle to select micropores at different positions in the first direction; the limiting portion is fixed to the positioning portion; one end of the pushing portion is slidably arranged in the positioning portion, and the other end is movably connected to the limiting portion. The pushing portion cooperates with the limiting portion to enable the microneedle to select micropores at different positions in the second direction.
[0009] The instrument has at least the following beneficial effects:
[0010] The operation is simple. During the treatment process, the catheter located in the human urethra remains stationary with the support portion, and there is no relative displacement or rotation between the two. The operator only adjusts the handle brake to adjust the insertion position of the microneedle with multiple degrees of freedom to efficiently treat the prostate tissue near the urethra, systematically treat multiple focal points in the prostate while reducing unnecessary damage caused by friction and pulling between the instrument and the urethra, protecting the urethra and improving the patient's treatment experience.
[0011] In some embodiments, the support portion and the positioning portion are slidably clamped through a chute matching the micropores in the first direction, and the pushing portion and the limiting portion are slidably clamped through a chute matching the micropores in the second direction.
[0012] With such a setting, the position adjustment of the microneedle in the first direction is realized through the sliding clamping of the support portion and the positioning portion. The position adjustment of the microneedle in the second direction is realized through the movable clamping of the pushing portion and the limiting portion.
[0013] In some embodiments, the microneedle includes: a first insertion portion and a second insertion portion, which are used to respectively extend out of the catheter through different micropores and insert into the prostate tissue at a first depth and a second depth. The first insertion portion and the second insertion portion are respectively provided with a first conductive region and a second conductive region, and the position of the first conductive region on the first insertion portion is the same as or different from the position of the second conductive region on the second insertion portion.
[0014] With such a setting, the first conductive region of the first insertion portion and the second conductive region of the second insertion portion are respectively inserted into the prostate tissue, which is convenient for pre-planning the treatment points, treating at different positions, reducing the operation time and reducing the patient's pain.
[0015] In some embodiments, the first insertion portion and the second insertion portion arranged at intervals in the first direction are used to respectively insert into the prostate tissue through different micropores in the first direction. The tip of the first insertion portion is provided with a first conductive region, and the second conductive region is provided at a position away from the tip of the second insertion portion. The first depth is less than the second depth.
[0016] With such a setting, the regional treatment time is reduced and the efficiency is improved. At the same time, the second conductive region near the urethra on the second insertion part and the first conductive region on the first insertion part jointly construct a large-scale three-dimensional energy field in the prostate tissue, completely covering the treatment blind area near the urethra to prevent the recurrence of prostate hyperplasia caused by incomplete ablation.
[0017] In some embodiments, the first insertion part and the second insertion part spaced in the second direction are used to penetrate into the prostate tissue from different micropores in the second direction respectively. The first conductive region and the second conductive region are respectively arranged at positions of the first insertion part and the second insertion part far from the tip, and the first depth is less than or equal to the second depth.
[0018] With such a setting, except for the regions where the first insertion part and the second insertion part are located, the prostate tissue between the two insertion parts, especially near the urethra, can be evenly ablated, and it is not easy to have residues leading to the recurrence of hyperplasia. At the same time, the treatment efficiency is improved and the pain felt is less.
[0019] In some embodiments, the microneedle includes: a first insertion part for extending a catheter from a micropore and penetrating into the prostate tissue to a first depth, and a plurality of first conductive regions and second conductive regions are arranged at intervals on the first insertion part.
[0020] With such a setting, only the first conductive region of the first insertion part of the microneedle can work to accurately eliminate the lesion, or the first insertion part can be configured to have the two conductive regions act simultaneously.
[0021] In some embodiments, the first conductive region and the second conductive region are configured to have the same or opposite polarities.
[0022] With such a setting, it realizes less trauma, deeper penetration, uniform energy distribution, and achieves a better treatment effect for treating larger-area lesions.
[0023] In some embodiments, the microneedle has a plurality of insertion parts, and the plurality of insertion parts are used to extend catheters from different micropores respectively and penetrate into the prostate tissue at different depths in a lattice arrangement, and each insertion part is provided with a conductive region.
[0024] With such a setting, an interlaced and dense energy field is formed in different directions in the prostate tissue, realizing efficient treatment with a large area and uniform energy action.
[0025] In some embodiments, the microneedle has a plurality of insertion parts, and the plurality of insertion parts are used to extend catheters from different micropores respectively and penetrate into the prostate tissue at different depths in a lattice arrangement, and one or more insertion parts do not have a conductive region.
[0026] With such a setting, multiple three-dimensional lattice energy fields are formed. By adjusting the energy action mode through an external device, the three-dimensional lattice energy field can also be changed, effectively treating the lesions at any coordinate position within the prostate tissue, reducing the operation time, and alleviating the pain of the patient.
[0027] In some of these embodiments, the catheter further includes: an inflatable balloon and a fluid port for delivering fluid to the inflatable balloon through the lumen.
[0028] With such a setting, the inflatable balloon can be inflated within the bladder, which is beneficial for the positioning and use of the catheter in the urethra. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 It is a schematic diagram of the overall structure of an instrument for treating benign prostatic hyperplasia in an embodiment of the present disclosure;
[0030] Figure 2 It is an exploded view of an instrument for treating benign prostatic hyperplasia in an embodiment of the present disclosure;
[0031] Figure 3 It is a cross-sectional view of an instrument for treating benign prostatic hyperplasia in an embodiment of the present disclosure;
[0032] Figure 4 It is a cross-sectional view of an instrument for treating benign prostatic hyperplasia in an embodiment of the present disclosure;
[0033] Figure 5 It is a schematic diagram of the overall structure of the positioning part in an embodiment of the present disclosure;
[0034] Figure 6 It is a schematic diagram of the overall structure of the pushing part in an embodiment of the present disclosure;
[0035] Figure 7 It is a schematic diagram of the first piercing part and the second piercing part of the microneedle and the catheter in an embodiment of the present disclosure;
[0036] Figure 8 It is a side view of the first piercing part and the second piercing part of the microneedle, the catheter, and the prostate tissue in an embodiment of the present disclosure;
[0037] Figure 9 It is a schematic diagram of the first piercing part and the second piercing part of the microneedle and the catheter in an embodiment of the present disclosure;
[0038] Figure 10 It is a schematic diagram of the first conductive region and the second conductive region of the microneedle in an embodiment of the present disclosure;
[0039] Figure 11 It is a schematic diagram of multiple piercing parts of the microneedle in an embodiment of the present disclosure;
[0040] Figure 12 Schematic diagram between multiple piercing parts of the microneedle, the catheter and the prostate tissue in the embodiments of the present disclosure;
[0041] Figure 13 Overall structural schematic diagram of the catheter in the embodiments of the present disclosure.
[0042] Reference numerals:
[0043] 100, an instrument for treating benign prostatic hyperplasia; 1, catheter; 11, micropores; 12, inflatable balloon; 2, microneedle; 20, piercing part; 21, first piercing part; 22, second piercing part; 23, conductive area; 231, first conductive area; 232, second conductive area; 3, handle brake; 31, support part; 311, first chute; 32, positioning part; 33, limiting part; 34, pushing part; 341, second chute; 200, prostate tissue. Detailed implementation manners
[0044] To make the above-mentioned objects, features and advantages of the embodiments of the present disclosure more obvious and understandable, the following will describe in detail the specific implementation manners of the embodiments of the present disclosure with reference to the accompanying drawings. Many specific details are set forth in the following description in order to fully understand the embodiments of the present disclosure. However, the embodiments of the present disclosure can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without departing from the connotation of the embodiments of the present disclosure. Therefore, the embodiments of the present disclosure are not limited by the specific embodiments disclosed below.
[0045] In the description of the embodiments of the present disclosure, it should be understood that the terms "center", "longitudinal", "transverse", "upper", "lower", "front", "rear", "vertical", "perpendicular", "horizontal", "inner", "outer", "axial", "radial", "circumferential", etc. indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings, and are only for the convenience of describing the embodiments of the present disclosure and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore should not be construed as a limitation to the embodiments of the present disclosure.
[0046] In addition, the terms "first", "second", "third", etc. are only used for descriptive purposes and cannot be construed as indicating or implying relative importance or implicitly indicating the quantity of the indicated technical features. Thus, features defined with "first" and "second" may explicitly or implicitly include at least one of such features. Exemplarily, the first piercing part may also be referred to as the second piercing part, and the second piercing part may also be referred to as the first piercing part. In the description of the present invention, the meaning of "a plurality" is at least two, such as two, three, etc., unless otherwise specifically defined.
[0047] In the embodiments of the present disclosure, unless otherwise clearly specified or limited, terms such as "connected" and "coupled" shall be understood in a broad sense. For example, it may be a fixed connection, a detachable connection, or an integral one; it may be a flexible connection or a rigid connection in at least one direction; it may be a mechanical connection or an electrical connection; it may be directly connected or indirectly connected through an intermediate medium, or there may be an intermediate medium while being directly connected, and it may also be the internal communication between two components or the interaction relationship between two components, unless otherwise clearly limited. Terms such as "installed", "set", and "fixed" can be understood in a broad sense as connections. For those of ordinary skill in the art, the specific meanings of the above terms in the embodiments of the present disclosure can be understood according to specific circumstances.
[0048] The present disclosure relates to the technical field of medical devices. In combination with Figure 1 , Figure 2 , an instrument 100 for treating benign prostatic hyperplasia includes a catheter 1, microneedles 2, and a handle brake 3, and the handle brake 3 is used to control the position of the microneedles 2 relative to the catheter 1.
[0049] The material of the catheter 1 is any suitable material that is flexible and biocompatible. For example, it may be any one of polyurethane, polyethylene terephthalate (PET), silicone rubber, natural latex, ethylene-propylene-diene copolymer, butyl rubber, and styrene-isobutylene-styrene copolymer.
[0050] It should be noted that for the distal end and proximal end referred to in the present disclosure, based on the operator, the end close to the operator is the proximal end, and the end far from the operator is the distal end. In the present disclosure, the first direction and the second direction are the axial direction and the circumferential direction respectively; or the first direction is the circumferential direction and the second direction is the axial direction.
[0051] The catheter 1 is provided with a plurality of micropores 11 spaced along the first direction and the second direction; the microneedles 2 are slidably disposed inside the catheter 1, the proximal end is located inside the handle brake 3 and fixed to the pushing portion 34, and the distal end can extend out of the catheter 1 through the micropores 11. The handle brake 3 includes a support portion 31, a positioning portion 32, a limiting portion 33, and a pushing portion 34 that are connected in sequence.
[0052] Exemplarily, the support portion 31, the positioning portion 32, the limiting portion 33, and the pushing portion 34 may be circular tubular members with a certain length and are nested axially in sequence to form the handle brake 3. It should be noted that using other shaped structures known to those skilled in the art also falls within the protection scope of the present disclosure.
[0053] Wherein, one end of the support portion 31 is connected to the proximal end of the catheter 1, and the other end is movably connected to the positioning portion 32; the positioning portion 32 cooperates with the support portion 31 to enable the microneedle 2 to select micropores 11 at different positions in the first direction; the limiting portion 33 is fixed to the positioning portion 32; one end of the pushing portion 34 is slidably disposed within the positioning portion 32, and the other end is movably connected to the limiting portion 33, and the pushing portion 34 cooperates with the limiting portion 33 to enable the microneedle 2 to select micropores 11 at different positions in the second direction.
[0054] Please refer to Figure 3 , before the distal end of the catheter 1 reaches the prostate tissue 200 to be treated through the urethra, while the handle brake 3 is pushed deep into the urethra as a whole, a distance is maintained between the proximal end of the pushing portion 34 and the limiting portion 33, so that the piercing portion of the microneedle 2 is completely within the catheter 1.
[0055] Please refer to Figure 4 , after determining the area to be treated, the operator pushes the pushing portion 34 distally, synchronously driving the microneedle 2 to slide distally. Eventually, the piercing portion 20 of the microneedle 2 pierces into a certain area through the micropore 11, and radiofrequency energy is applied to the treatment area to treat benign prostatic hyperplasia.
[0056] After completing the treatment of a certain area, the pushing portion 34 can be pulled proximally to retract the piercing portion 20 of the microneedle 2 piercing into the prostate tissue 200 into the catheter 1. In addition, the positions between the positioning portion 32 and the support portion 31 can be adjusted to change the treatment area in the first direction, and the positions between the pushing portion 34 and the limiting portion 33 can be adjusted to change the treatment area in the second direction, realizing the treatment of benign prostatic hyperplasia with multiple degrees of freedom.
[0057] In some embodiments, the support portion 31 and the positioning portion 32 are slidably clamped through a chute matching the micropore 11 in the first direction to realize the position adjustment of the microneedle 2 in the first direction, and the pushing portion 34 and the limiting portion 33 are slidably clamped through a chute matching the micropore 11 in the second direction to realize the position adjustment of the microneedle 2 in the second direction.
[0058] Exemplarily, refer to Figure 5 , six first chutes 311 are formed on the inner wall of the support portion 31, and the adjacent first chutes 311 are spaced 5 mm apart. A first slider protrudes from the outer wall of the positioning portion 32. By rotating the positioning portion 32 to select different first chutes 311 and making the first slider slide along the selected first chute 311, finally the first slider is stuck so that the piercing portion 20 pierces into the prostate tissue 200 from the micropore corresponding to the selected first chute 311. Refer to Figure 6, a plurality of second sliding grooves 341 are formed in the outer wall of the pushing part 34, and corresponding second sliding blocks are provided on the inner wall of the limiting part 33. By rotating the pushing part 34, different second sliding grooves 341 are selected so that the piercing part 20 pierces into the prostate tissue 200 from the micropores corresponding to the selected second sliding grooves 341. Exemplarily, a second sliding groove 341 is formed in the outer wall of the pushing part 34 every 90°.
[0059] During the whole treatment process, there is no displacement or rotation between the catheter 1 located in the urethra and the supporting part 31. The operator only adjusts the piercing position of the micro needle 2 by adjusting the handle brake 3, which realizes efficient and multi-degree-of-freedom treatment of multiple prostate lesions while reducing unnecessary injuries caused by friction and pulling between the instrument and the urethra, and improves the patient's treatment experience.
[0060] The micro needle 2 can be a metal or alloy with certain hardness and ductility, such as metals or alloys of platinum, tungsten, titanium, stainless steel, nickel. It can also be a superelastic material, such as nitinol alloy or superelastic stainless steel. It can also be a composite conductive material.
[0061] Please refer to Figure 7 、 Figure 8 and Figure 9 , the distal end of the micro needle 2 has: a first piercing part 21 and a second piercing part 22. During treatment, the first piercing part 21 and the second piercing part 22 at the distal end of the micro needle 2 can be respectively pierced into the prostate tissue 200 to be treated from different micropores in the first direction or the second direction through the guiding channels provided in the catheter 1 by operating the handle brake.
[0062] Specifically, after determining the area to be treated, the outer wall of the catheter 1 is close to the prostate tissue 200. The first piercing part 21 pierces into the prostate tissue 200 to a first depth H1 from a micropore 11 of the catheter 1, and the second piercing part 22 pierces into the prostate tissue 200 to a second depth H2 from another micropore 11. First conductive areas 231 and second conductive areas 232 for applying radio frequency energy to the treatment area are respectively provided at the same or different positions on the first piercing part 21 and the second piercing part 22.
[0063] Please refer to Figure 7 、 Figure 8 , during treatment, the first piercing part 21 and the second piercing part 22 respectively extend out of the outer wall of the catheter 1 from the micropores in the axial direction and pierce into the prostate to a first depth H1 and a second depth H2. First conductive areas 231 and second conductive areas 232 are respectively arranged at the distal end of the first piercing part 21 and the position of the second piercing part 22 close to the catheter 1. The first conductive areas 231 and the second conductive areas 232 can be configured in a monopole or bipolar mode to apply radio frequency energy to the prostate tissue 200.
[0064] In addition, the position of the first conductive region 231 on the first insertion portion 21 may be the same as the position of the second conductive region 232 on the second insertion portion 22, that is, the first conductive region 231 and the second conductive region 232 may both be disposed at the proximal ends of the corresponding insertion portions 20.
[0065] In this embodiment, two insertion portions 20 with a larger treatment area are used. Compared with a single insertion portion 20, multiple points can be treated simultaneously, reducing the regional treatment time and improving the efficiency. At the same time, by configuring the first conductive region 231 and the second conductive region 232 in a monopolar or bipolar mode, the second conductive region 232 near the urethra position on the second insertion portion 22 and the first conductive region 231 located on the first insertion portion 21 jointly construct a large-scale three-dimensional energy field within the prostate tissue 200, completely covering the treatment blind area near the urethra to prevent the recurrence of prostate hyperplasia caused by incomplete ablation.
[0066] Please refer to Figure 9 , the first insertion portion 21 and the second insertion portion 22 can also respectively extend from the circumferential micropores out of the outer wall of the catheter 1 and penetrate into the prostate to the first depth H1 and the second depth H2. The proximal ends of the first insertion portion 21 and the second insertion portion 22 are respectively provided with a first conductive region 231 and a second conductive region 232 for applying radio frequency energy to the prostate tissue 200. During treatment, the first conductive region 231 and the second conductive region 232 can be configured in a monopolar or bipolar mode.
[0067] In this embodiment, except for the regions where the first insertion portion 21 and the second insertion portion 22 are located, the prostate tissue 200 between the two insertion portions 20, especially near the urethra, can be uniformly ablated, and it is not easy to have residues leading to the recurrence of hyperplasia. At the same time, the treatment efficiency is improved and the pain felt is less.
[0068] In some embodiments, there may also be only one first insertion portion 21 at the distal end of the microneedle 2, on which a plurality of first conductive regions 231 and second conductive regions 232 for applying radio frequency energy are arranged at intervals. The first conductive region 231 and the second conductive region 232 can be configured in a monopolar or bipolar mode.
[0069] Please refer to Figure 10 , the first conductive region 231 and the second conductive region 232 are arranged at intervals along the axial direction of the microneedle 2, and the portion between the first conductive region 231 and the second conductive region 232 is an insulating region. The monopolar or bipolar mode can be used to treat the prostate tissue, and it has a good effect within a certain treatment area.
[0070] Exemplarily, the first conductive region 231 and the second conductive region 232 can both be annular. It can be understood that the first conductive region 231 and the second conductive region 232 can also be other shapes such as dot-shaped or spiral-shaped. For example, the first conductive region 231 and the second conductive region 232 arranged opposite to each other along the diameter direction are both dot-shaped. The first conductive region 231 and the second conductive region 232 are arranged in a double helix along the axial direction.
[0071] In some embodiments, the microneedle 2 has a plurality of piercing portions 20, and the plurality of piercing portions 20 respectively extend from different micropores 11 out of the catheter 1 and pierce into different depths of the prostate tissue 200 to be treated.
[0072] Please refer to Figure 11 、 Figure 12 , and the plurality of piercing portions 20 arranged in a lattice arrangement pierce into different depths of the prostate tissue 200, and the conductive regions 23 on each piercing portion 20 form a three-dimensional lattice dot energy field in the prostate tissue 200.
[0073] Exemplarily, the plurality of piercing portions 20 are provided with conductive regions 23 at the same or different positions, and some piercing portions 20 may not be provided with conductive regions 23. The conductive regions 23 can be configured in a monopolar or bipolar mode to apply radio frequency energy to the prostate tissue 200.
[0074] In this embodiment, the conductive regions 23 of different piercing portions 20 form a three-dimensional lattice dot energy field in various situations. By adjusting the energy action mode through an external device, the three-dimensional lattice dot energy field can be changed. Compared with other embodiments of the present disclosure, the treatment area is larger and the energy action in the treatment area is uniform, realizing systematic and effective treatment of lesions at any coordinate position in the prostate tissue 200, reducing the operation time and reducing the pain of the patient.
[0075] Refer to Figure 13 , in some embodiments, the catheter 1 further includes: an inflatable balloon 12 and a fluid port (not shown in the figure), and the fluid port is used to convey fluid to the inflatable balloon 12 through the lumen in the catheter 1.
[0076] Exemplarily, the fluid port is communicated with the inflatable balloon 12 through the lumen of the catheter 1. The inflatable balloon 12 is located at a specific position of the catheter 1 and enters the urethra when in a contracted state. When the inflatable balloon 12 reaches the bladder, saline, air or other forms of fluid are introduced into the lumen of the catheter 1 from the fluid port so that the inflatable balloon 12 expands and gets stuck inside the bladder to position the catheter 1. After the treatment is completed, the fluid in the inflatable balloon 12 can be discharged from the fluid port to remove the catheter 1.
[0077] Each technical feature of the embodiments disclosed above can be combined arbitrarily. For the sake of brevity of description, not all possible combinations of the various technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, it should be considered as falling within the scope described in this specification.
[0078] The embodiments disclosed above only represent several implementation manners of the present utility model, and their descriptions are relatively specific and detailed. However, it should not be construed as a limitation on the scope of the utility model patent. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present utility model, several modifications and improvements can still be made, and these all belong to the protection scope of the present utility model. Therefore, the protection scope of the present utility model patent shall be subject to the appended claims.
Claims
1. An instrument for treating benign prostatic hyperplasia, characterized in that, Comprising: A catheter having a plurality of micropores spaced along a first direction and a second direction; Microneedles slidably disposed inside the catheter, with the distal ends capable of extending out of the catheter through the micropores; And A handle brake including a support portion, a positioning portion, a limiting portion, and a pushing portion connected in sequence. One end of the support portion is connected to the proximal end of the catheter, and the other end is movably connected to the positioning portion; the positioning portion cooperates with the support portion to enable the microneedles to select micropores at different positions along the first direction; the limiting portion is fixed to the positioning portion; One end of the pushing portion is slidably disposed within the positioning portion, and the other end is movably connected to the limiting portion. The pushing portion cooperates with the limiting portion to enable the microneedles to select micropores at different positions along the second direction.
2. The instrument for treating benign prostatic hyperplasia according to claim 1, wherein The support portion and the positioning portion are slidably clamped through a chute matching the micropores in the first direction, and the pushing portion and the limiting portion are slidably clamped through a chute matching the micropores in the second direction.
3. The instrument for treating benign prostatic hyperplasia according to claim 1, wherein The microneedles include: a first piercing portion and a second piercing portion for respectively extending out of the catheter through different micropores and piercing into the prostate tissue to a first depth and a second depth. The first piercing portion and the second piercing portion are respectively provided with a first conductive region and a second conductive region, and the position of the first conductive region on the first piercing portion is the same as or different from the position of the second conductive region on the second piercing portion.
4. A device for treating benign prostatic hyperplasia according to claim 3, wherein, The first piercing portion and the second piercing portion spaced along the first direction are used for respectively piercing into the prostate tissue through different micropores in the first direction. The tip of the first piercing portion is provided with the first conductive region, and the second conductive region is provided at a position away from the tip of the second piercing portion. The first depth is less than the second depth.
5. An instrument for treating benign prostatic hyperplasia according to claim 3, characterized in that, The first piercing portion and the second piercing portion spaced along the second direction are used for respectively piercing into the prostate tissue through different micropores in the second direction. The first conductive region and the second conductive region are respectively provided at positions away from the tips of the first piercing portion and the second piercing portion. The first depth is less than or equal to the second depth.
6. The device for treating benign prostatic hyperplasia according to claim 1, characterized in that, The microneedles include: a first piercing portion for extending out of the catheter through the micropore and piercing into the prostate tissue to a first depth. A plurality of first conductive regions and second conductive regions are arranged at intervals on the first piercing portion.
7. A device for treating benign prostatic hyperplasia according to any one of claims 4 to 6, characterized in that, The first conductive region and the second conductive region are configured to have the same or opposite polarities.
8. An instrument for treating benign prostatic hyperplasia according to claim 1, characterized in that, The microneedles have a plurality of piercing portions. The plurality of piercing portions are used for respectively extending out of the catheter through different micropores and piercing into the prostate tissue at different depths in a lattice arrangement. Each piercing portion is provided with a conductive region.
9. An apparatus for treating benign prostatic hyperplasia according to claim 1, wherein, The microneedles have a plurality of piercing portions. The plurality of piercing portions are used for respectively extending out of the catheter through different micropores and piercing into the prostate tissue at different depths in a lattice arrangement. More than one of the piercing portions has no conductive region.
10. The instrument for treating benign prostatic hyperplasia according to claim 1, wherein, The catheter further includes: an inflatable balloon and a fluid port for delivering fluid to the inflatable balloon through the lumen of the catheter.